Lenacapavir’s $6,000 Price Tag Threatens HIV Access
The FDA approved lenacapavir, an HIV shot with over 99% efficacy, but its $6,000 price tag threatens access. This cost barrier risks excluding vulnerable populations in low-income regions from the tre
Business Insider Mkt — 31 July 2026
Text:
18
0
0
The FDA has cleared lenacapavir, a long‑acting HIV shot that could cut infection risk to almost zero, but the drug’s price threatens to keep it out of
Read Full Story at Business Insider Mkt → Sources
🏥 Health
Sudan war cuts subsidies, spikes cancer drug prices
🏥 Health
Oxford administers experimental Bundibugyo Ebola vaccine to first patient
🏥 Health
Ebola death toll in DR Congo surpasses 1,000
🏥 Health
Why the U.S. is losing the global sunscreen race
🏥 Health
UK humanitarian worker monitored for Ebola in London hospital
🏥 Health
African countries are facing rising rates of cancer. What's being done about it?
